Quality of life in patients with graves ophthalmopathy

Transactions of the American Ophthalmological Society

Volumn 103, Issue , 2005, Pages 368-411

  Patrick Yeatts, R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLURRED VISION; COMPARATIVE STUDY; CONTROLLED STUDY; DIPLOPIA; DISEASE SEVERITY; DRY EYE; ENDOCRINE OPHTHALMOPATHY; FEMALE; GRAVES DISEASE; HUMAN; MALE; MENTAL HEALTH; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF CONCEPT; SLEEP; SOCIAL STATUS; THYROID DISEASE; VALIDATION PROCESS; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; EYE DISEASES; FEMALE; GRAVES OPHTHALMOPATHY; HEALTH STATUS; HUMANS; INTERPERSONAL RELATIONS; MALE; MENTAL HEALTH; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; VISION DISORDERS; WORK;

EID: 29944445465     PISSN: 15456110     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Bartley GB, Fatourechi V, Kadramas EF, et al. Clinical features of Graves' ophthalmopathy in an incident cohort. Am J Ophthalmol 1996;121:284-290.
2. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in an incident cohort. Ophthalmology 1996;106:958-962.
3. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-793.
4. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet 1991;338:25-28.
5. Hales IB, Rundle FF. Ocular changes in Graves' disease: a long-term follow-up study. Q J Med 1960;29:113-126.
6. Terwee CB, Dekker FW, Prummel MF, et al. Graves' ophthalmopathy through the eyes of the patient: a state of the art on health-related quality of life assessment. Orbit 2001;20:281-290.
7. Bartley GW. Evolution of classification systems for Graves' ophthalmopathy. Ophthal Plast Reconstr Surg 1995;11:229-237.
8. Werner SC. Classification of the eye changes of Graves' disease. J Clin Endocrinol Metab 1969;29:982-984.
9. Werner SC. Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol 1977;83:725-727.
10. Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73:639-644.
11. Bartalena L, Marcocci C, Bogazzi F, et al. A new ophthalmopathy index for quantification of eye changes of Graves' disease. Acta Endocrinol (Copenh) 1998;121(suppl 2):190-192.
12. Feldon SE, Unsöld R. Graves' ophthalmopathy evaluated by infrared eye-movement recordings. Arch Ophthalmol 1982;100:324-328.
13. Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 1987;16:391-407.
14. Van Dyk HJL. Orbital Graves' disease: a modification of the "NO SPECS" classification. Ophthalmology 1881;88:479-483.
15. Pinchera A, Wiersinga WM, Glinoer D, et al. Classification of eye changes of Graves' disease. Thyroid 1992;2:235-236.
16. Frueh BR. Why the NOSPECS classification of Graves' eye disease should be abandoned with suggestions for the characterization on this disease. Thyroid 1992;2:85-88.
17. Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy. Br J Ophthalmol 1998:82:773-779.
18. Brown MM. Quality-of-life instruments. Evidence-Based Eye Care 2001;2:196-197.
19. Parrish RK. Visual impairment, visual functioning and quality of life assessments on patients with glaucoma. Trans Am Ophthalmol Soc 1996;94:919-1028.
20. Anonymous. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 1993;2:153-59.
21. Vitale S, Schein OD. Quantitative research in functional visual loss. Int Ophthalmol Clin 2003;43:17-30.
22. Ware JE. Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36) I: conceptual framework and item selection. Med Care 1992;30:473-481.
23. Stewart AL, Hayes RD, Ware JE. The MOS Short-form General Health Survey: reliability and validity in a patient population. Med Care 1988;26:724-35.
24. Bergner M, Bobbitt RA, Pollard, et al. The Sickness Impact Profile: conceptual and methodology for the development of a health status measure. Int J Health Serv 1976;6:393-415.
25. Bassatt SS, Folstein MF. Cognitive impairment and functional disablility in the absence of psychiatric diagnosis. Psychiatr Med 1991;21:77-84.
26. Anderson RT, Aaronson NK, Wilkin D. Critical review of the international assessment of health related quality of life. Qual Life Res 1993;2:369-95.
27. Schag CA, Ganz PA, Heinrich RL. Cancer Rehabilitation Evaluation System-short form (CARES-SF). A cancer specific rehabilitation and quality of life instrument. Cancer 1991;68:1406-13.
28. Bottomley A, Vanvoorden V, Flechtner H, et al. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer 2003;39:275-85.
29. Naughton MJ, Wiklund I. A critical review of dimension-specific measures of health-related quality of life in cross-cultural research. Qual Life Res 1993;2:397-432.
30. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995;82:216-222.
31. Irvine EJ. Quality of life: rational and methods for developing a disease-specific instrument for inflammatory bowel disease. Scand J Gastroenterol 1993;199:22-27.
32. Wyrwich KW, Nelson HS, Tierney WM, et al. Clinically important differences in health-related quality of life for patients with asthma: an expert consensus panel report. Ann Allergy Asthma Immunol 2003;1:148-53.
33. Hays RD, Kallich JD, Mapes DL, et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994; 4:221-231.
34. Anderson R, Rajagopaian R. Responsiveness of the dermatology-specific quality of life (DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial. Qual Life Res 1998;7:723-734.
35. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-713.
36. Zadnik K, Barr JT, Edrington TB, et al. Baseline findings in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study. Invest Ophthalmol Vis Sci 1998;39:2537-2546.
37. Janz, NK, Wren, PA, Lichter, PR, et al. Quality of life in newly diagnosed glaucoma patients: the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 2001;108:887-897.
38. Musch, DC, Lichter, PR, Guire, KE, et al. The Collaborative Initial Glaucoma Treatment Study (CIGTS): study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 1999;106:653-662.
39. Margolis MK, Coyne K, Kennedy-Martin T, et al., Vision-specific instruments for the assessment of health-related quality of life and visual functioning: a literature review. Pharmacoeconomics 2002;20:791-812.
40. Scott IU, Schein OD, West S, et al. Functional status and quality of life measurement among ophthalmic patients. Arch Ophthalmol 1994;112:329-335.
41. Desai P, Reidy A, Minassian DC, et al. Gains from cataract surgery: visual function and quality of life. Br J Ophthalmol 1996;80:868-873.
42. Mills RP. Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Trans Am Ophthalmol Soc 1998;96:753-812.
43. Mangione CM, Berry S, Spritzer K, et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol 1998;116:227-233.
44. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050-1058.
45. Clemons TE, Chew EY, Bressler SB, et al. National Eye Institute visual function questionnaire in the age-related eye disease study (AREDS): AREDS report no. 10. Arch Ophthalmol 2003;121:211-217.
46. Miskala PH, Hawkins BS, Mangione CM, et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization-SST report no.1. Arch Ophthalmol 2003;121:531-539.
47. Brody BL, Roch-Levcq AC, Gamst AC, et al. Self-management of age-related macular degeneration and quality of life: a randomized controlled trial. Arch Ophthalmol 2002;120:1477-1483.
48. Nichols KK, Mitchell GL, Zadnik K. Performance and repeatability of the NEI-VFQ-25 in patients with dry eye. Cornea 2002;21:578-583.
49. Cruickshanks KJ, Fryback DG, Nondahl DM, et al. Treatment choice and quality of life in patients with choriodal melanoma. Arch Ophthalmol 1999;117:461-467.
50. Deramo VA, Cox TA, Syed AB, et al. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003;121:1297-1302.
51. Parrish RK, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 1997;115:1447-1455.
52. Jampel HD. Glaucoma patients' assessment of their visual function and quality of life. Trans Am Ophthalmol Soc 2001;99:301-317.
53. Terwee CB, Gerding MN, Dekker FW, et al. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy. J Clin Epidemiol 1999;9:875-884.
54. Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol 2001;54:391-398.
55. Egle UT, Kahaly GJ, Petrak F, et al. The relevance of physical and psychosocial factors for the quality of life in patients with thyroid associated orbitopathy (TAO). Exp Clin Endocrinol Diabetes 1999;107(suppl 5):S168-171.
56. Gerding MN, Terwee CB, Dekker FW, et al. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid 1997;7:885-889.
57. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. Can Med Assoc 1986;134:889-899.
58. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27:S217-32.
59. Wolffsohn JS, Cochrane AL, Watt NA. Implementation methods for vision related quality of life questionnaires. Br J Ophthalmol 2000;84:1035-1040.
60. Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association [letter]. J Clin Endocrinol Metab 1977;44:203-204.
61. Perros P, Crombie AL, Matthews JNS, et al.. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol 1993;38:367-372.
62. Bartalena L, Marcocci C, Pinchera A. Orbital radiotherapy for Graves' ophthalmopathy [editorial]. J Clin Endocrinol Metab 2004;89:13-14.
63. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, single-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001;108:1523-1534.
64. Bartalena L, Marcocci C, Bagazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338: 73-78.